Table 5.
Best overall response based on modified World Health Organization assessment and length of time on study
| Brivanib dose (mg) (assessable patientsa) | All doses, n (%) | 180 (3) | 320 (14) | 600 (3) | 800 C (20) | 800 I (11) | 400 b.i.d. (13) | 1000 (4) |
| Response, n | ||||||||
| Partial response, n | 2 (3) | 1b | 1c | |||||
| Stable disease | 24 (35) | 1 | 4 | 1 | 8 | 5 | 4 | 1 |
| Progressive disease | 32 (47) | 2 | 9 | 1 | 8 | 5 | 6 | 1 |
| Not assessable | 10 (15) | 1 | 4 | 1 | 3 | 1 | ||
a
At least one post-treatment scan.
b
Renal cell carcinoma.
c
Ampulla of Vater.
C, continuous; I, intermittent.